EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs

Marie Wijk iD, Kamunkhwala Gausi iD, Samantha Malatesta, Sarah E Weber, Richard Court, Bronwyn Myers, Tara Carney, Charles D H Parry, C Robert Horsburgh iD, Laura F White, Lubbe Wiesner iD, Robin M Warren und 5 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Marie Wijk und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Cape Town, Cape Town, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Rifampin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In South Africa, an estimated 11% of the population have high alcohol use, a major risk factor for TB. Alcohol and other substance use are also associated with poor treatment response, with a potential mechanism being altered TB drug pharmacokinetics.

Objectives

To investigate the impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs in participants with pulmonary TB.

Methods

We prospectively enrolled participants ≥15 years old, without HIV, and initiating drug-susceptible TB treatment in Worcester, South Africa. Alcohol use was measured via self-report and blood biomarkers. Other illicit substances were captured through a urine drug test. Plasma samples were drawn 1 month into treatment pre-dose, and 1.5, 3, 5 and 8 h post-dose. Non-linear mixed-effects modelling was used to describe the pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol. Alcohol and drug use were tested as covariates.

Results

The study included 104 participants, of whom 70% were male, with a median age of 37 years (IQR 27–48). Alcohol use was high, with 42% and 28% of participants having moderate and high alcohol use, respectively. Rifampicin and isoniazid had slightly lower pharmacokinetics compared with previous reports, whereas pyrazinamide and ethambutol were consistent. No significant alcohol use effect was detected, other than 13% higher ethambutol clearance in participants with high alcohol use. Methaqualone use reduced rifampicin bioavailability by 19%.

Conclusion

No clinically relevant effect of alcohol use was observed on the pharmacokinetics of first-line TB drugs, suggesting that poor treatment outcome is unlikely due to pharmacokinetic alterations. That methaqualone reduced rifampicin means dose adjustment may be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsRifampinHumansMaleAdultFemaleSouth AfricaMiddle AgedProspective StudiesIsoniazidAlcohol DrinkingTuberculosis, PulmonarySubstance-Related DisordersPyrazinamideEthambutolYoung Adult

Substanzen

Antitubercular AgentsRifampinIsoniazidPyrazinamideEthambutol

Autor:innen und Institutionen

  • Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.
  • Section of Infectious Diseases, Boston University School of Medicine and Boston Medical Centre, Boston, MA, USA.
  • Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.
  • Curtin enAble Institute, Curtin University, WA, Australia.
  • Mental Health, Alcohol, Substance Use and Tobacco Research Unit, South African Medical Research Council, Cape Town, South Africa.

ORCID-Profile: Marie Wijk, Kamunkhwala Gausi, C Robert Horsburgh, Lubbe Wiesner, Caitlin Uren, Helen McIlleron, Frank Kloprogge, Paolo Denti

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • Wellcome Trust Sir Henry Dale Fellowship
  • United States National Institute of Allergy and Infectious Diseases
  • Wellcome Trust
  • Adult Clinical Trial Group
  • National Institutes of Health

Zitieren

APA

Wijk, M., Gausi, K., Malatesta, S., Weber, S. E., Court, R., Myers, B., Carney, T., Parry, C. D. H., Horsburgh, C. R., White, L. F., Wiesner, L., Warren, R. M., Uren, C., McIlleron, H., Kloprogge, F., Denti, P., & Jacobson, K. R. (2024). The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae206

Vancouver

Wijk M, Gausi K, Malatesta S, Weber SE, Court R, Myers B, et al. The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae206

BibTeX
@article{Wijk2024,
  author = {Wijk, Marie and Gausi, Kamunkhwala and Malatesta, Samantha and Weber, Sarah E and Court, Richard and Myers, Bronwyn and Carney, Tara and Parry, Charles D H and Horsburgh, C Robert and White, Laura F and Wiesner, Lubbe and Warren, Robin M and Uren, Caitlin and McIlleron, Helen and Kloprogge, Frank and Denti, Paolo and Jacobson, Karen R},
  title = {The impact of alcohol and illicit substance use on the pharmacokinetics of first-line TB drugs},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae206}
}
Kostenlos starten →